Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies.

"Kevin is joining us at a critical point in Enumeral's evolution, and we welcome his operational and financial expertise as we build our investor base, enter strategic collaborations and develop a pipeline of immunomodulators."
"Kevin's experiences working with biotechnology companies developing targeted therapies, including antibodies, are directly relevant to Enumeral's platform and business goals," said Arthur H. Tinkelenberg, Ph.D., President, Chief Executive Officer and Co-Founder of Enumeral. "Kevin is joining us at a critical point in Enumeral's evolution, and we welcome his operational and financial expertise as we build our investor base, enter strategic collaborations and develop a pipeline of immunomodulators."

"As Enumeral is a newly public company with a technology broadly applicable across the rapidly changing immunotherapy space, this is an exciting time to join the organization," added Mr. Sarney. "I look forward to working with this innovative team and contributing to the company's value creation and execution of its business and program goals."

Prior to joining Enumeral, Mr. Sarney served as Vice President, Finance and Administration at Avaxia Biologics, a clinical-stage biopharmaceutical company developing gut-targeted therapeutics. Before Avaxia, he worked with various biotechnology and medical device companies in Vice President of Finance and Controller roles, having been the Corporate Controller and Principal Accounting Officer of Nitromed, Inc., a publicly traded, cardiovascular-focused pharmaceutical company. During his time at Nitromed, Mr. Sarney was responsible for SEC reporting, financial planning, risk management, treasury, the initiation of the company's Sarbanes-Oxley compliance efforts, and financial and accounting support. During his career, he held the position of audit supervisor within the technology assurance group of PricewaterhouseCoopers LLP. Mr. Sarney earned a B.S. in business management from the University of Hartford, an M.B.A. from Boston University and an M.A. in accounting from Suffolk University. Mr. Sarney is a certified public accountant in the Commonwealth of Massachusetts.

About Enumeral

Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. Our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations. www.enumeral.com

Contacts

For Enumeral Biomedical Holdings, Inc.
MacDougall Biomedical Communications
Charles Liles or Heather Savelle, +1-781-235-3060
[email protected] or [email protected]

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.